This article is more than 5 years old. Information may no longer be current.
Galapagos discontinues development of novel agent in UC
Click Here to Manage Email Alerts
Galapagos NV has announced it will discontinue clinical development of its G protein-coupled receptor 84 inhibitor, GLPG1205, in ulcerative colitis.
The ORIGIN phase 2a study of GLPG1205 demonstrated positive pharmacokinetics, safety and tolerability; however, the efficacy endpoints were not met in patients with UC, according to a press release.
The data showed GLPG1205 was not significantly superior to placebo as measured by partial Mayo scores, although the agent was shown to be safe and well-tolerated overall.
“Exposure data were in line with the healthy volunteer data from the previous phase 1 clinical study,” according to the press release.
Detailed data from the study will be published later this year, and Galapagos will determine whether GLPG1205 will be developed for other indications.